Session » RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

Date: Monday, November 9, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 1724

A Feasible and Efficient Approach to Implementing Rheumatoid Arthritis Disease Activity Measure in a Busy Rheumatology Clinic: A Quality Improvement Project

9:00AM-11:00AM: Abstract Number: 1745

A Novel Method for Predicting 1-Year Retention of Abatacept Using Machine Learning Techniques

9:00AM-11:00AM: Abstract Number: 1725

An Investigation of the Relationship Between Patient Reported Outcomes and Biomarkers in a Community Rheumatology Practice

9:00AM-11:00AM: Abstract Number: 1726

Assessment of the Components of RAPID3 Patient Reported Outcomes in an Community Rheumatology Practice

9:00AM-11:00AM: Abstract Number: 1746

Association of Obesity with Treatment Response to Methotrexate or Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1729

Associations Between Patient Reported Outcomes and Impairments of Work and Activity in Patients with Rheumatoid Arthritis Who Achieved Clinical Remission; Retrospective Analysis Using the IORRA Database

9:00AM-11:00AM: Abstract Number: 1762

Benefit and Risk Profiles of Janus Kinase Inhibitors Approved in the US for the Treatment of RA

9:00AM-11:00AM: Abstract Number: 1763

Blending Hierarchical Cluster Analysis and Cluster-Specific Regressions to Predict Clinical Outcome to Tofacitinib Treatment in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1755

Body Mass Index Trajectory and Variability in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1747

Brain fMRI Predicts Responses to Certolizumab Pegol in RA. an International, Multi-center, Randomized, Double-blind, Placebo-controlled Trial (PreCePRA)

9:00AM-11:00AM: Abstract Number: 1756

Comparable Long-Term Outcomes Among DAS28-ESR-based Remission Criteria and ACR/EULAR Definitions in Patients with Established Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1730

Comparison of MBDA Score, Patient Global Assessment and Evaluator Global Assessment for Predicting Risk of Radiographic Progression

9:00AM-11:00AM: Abstract Number: 1740

Determinants of Influenza Vaccine Hesitancy in Rheumatoid Arthritis According to the WHO-SAGE Matrix

9:00AM-11:00AM: Abstract Number: 1731

Development of a Disease Activity Index for Rheumatoid Arthritis Patients Using the HandScan

9:00AM-11:00AM: Abstract Number: 1714

Disease Activity Trajectories for Early and Established Rheumatoid Arthritis: Real World Results from a Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 1741

Does Preventive Care Matter? (in RA)

9:00AM-11:00AM: Abstract Number: 1735

Effect of Aerobic Land-based Exercise Intervention on Fatigue in Rheumatoid Arthritis: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 1748

Effects of Abatacept and Tumor Necrosis Factor Inhibitor on the Normal Glycosylated Hemoglobin Level in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1749

Efficacy of Filgotinib in Patients with Rheumatoid Arthritis with Poor Prognostic Factors: Post Hoc Analysis

9:00AM-11:00AM: Abstract Number: 1713

Exploring Novel Tenosynovitis and Combined Inflammation Imaging Outcomes: Results from a Randomized Controlled Trial in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1720

Factors Associated with an Increased Risk of Imminent Rheumatoid Arthritis in ACPA+ Individuals

9:00AM-11:00AM: Abstract Number: 1751

Forecasting Healthcare Utilization in Rheumatoid Arthritis: A Machine Learning Predictive Model of Emergency Department Visits and Prednisone Initiation in a Single Tertiary Academic Center

9:00AM-11:00AM: Abstract Number: 1736

Health Assessment Questionnaire Predicts All-Cause Mortality at One Year in Patients with Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1757

High-Intensity Interval Training Increases Rheumatoid Arthritis Cardiorespiratory Fitness in Association with Improvements in CD4+ T Cell and Skeletal Muscle Mitochondrial Metabolism

9:00AM-11:00AM: Abstract Number: 1717

Impact of Treatments on Favorable Outcome over the First 10 Years of Disease in Early Rheumatoid Arthritis: Results from a WCE Model in the ESPOIR Cohort

9:00AM-11:00AM: Abstract Number: 1718

Impact of Treatments on Radiographic Progression over the First 10 Years of Disease in Early Rheumatoid Arthritis: Results from the ESPOIR Cohort

9:00AM-11:00AM: Abstract Number: 1721

Increasing Autoantibody Positivity During Pre-RA Is Associated with the Imminent Development of Classifiable RA

9:00AM-11:00AM: Abstract Number: 1750

Longitudinal Change in the Central Nervous System Pain Response After Treatment with Certolizumab or Placebo. a Post-hoc Analysis from the Pre-CEPRA Trial

9:00AM-11:00AM: Abstract Number: 1715

Longitudinal Patterns of Remission in Real-World Early Rheumatoid Arthritis Patients: Results from the Canadian Early Arthritis Cohort (CATCH)

9:00AM-11:00AM: Abstract Number: 1732

Machine Learning Coupled with Patient Reported Outcome Data to Classify & Predict RA Disease Activity

9:00AM-11:00AM: Abstract Number: 1728

Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 Study

9:00AM-11:00AM: Abstract Number: 1739

Patients with Early Rheumatoid Arthritis Considered to Have a Favourable Risk Profile and Treated According to a Step-up Strategy Have an Increased Risk of Chronic Analgesic Consumption

9:00AM-11:00AM: Abstract Number: 1733

Patients with Rheumatoid Arthritis and Comorbid Depression Have High Levels of RAPID3 (Routine Assessment of Patient Index Data) and FAST3 (Fibromyalgia Assessment Screening Index) on a Multidimensional Health Assessment Questionnaire (MDHAQ)

9:00AM-11:00AM: Abstract Number: 1742

Patients’ and Rheumatologists’ Perceptions on Preventive Intervention in Rheumatoid Arthritis and Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1727

Patterns of Fatigue in Early RA over 10 Years: Results from the ESPOIR Cohort

9:00AM-11:00AM: Abstract Number: 1743

Perioperative Steroids in Rheumatoid Arthritis Patients Having Total Joint Replacements: Help or Harm?

9:00AM-11:00AM: Abstract Number: 1722

Predicting Rheumatoid Arthritis Using the Symptoms in Persons at Risk of Rheumatoid Arthritis (SPARRA) Questionnaire

9:00AM-11:00AM: Abstract Number: 1752

Prediction of Responder and Non-responder to JAK Inhibitors in Patients with Rheumatoid Arthritis: A Pilot Study with Integrative Cluster Analysis

9:00AM-11:00AM: Abstract Number: 1716

Predictors of Unacceptable Pain and Unacceptable Pain with Low Inflammation in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1758

Prevalence and Incidence of Infection and Venous Thromboembolism in Rheumatoid Arthritis Patients Newly Initiating Various DMARD Classes: Real-World Analysis of 2012–2016 US Medicare Data

9:00AM-11:00AM: Abstract Number: 1719

Prevalence and Trajectory of Erosions, Synovitis, and Bone Marrow Edema in Feet of Patients with Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1738

Promote Treat-to-Target for RA via Empowering Patients: A Cohort Study from China by Smart System of Disease Management (SSDM)

9:00AM-11:00AM: Abstract Number: 1723

RA Flare Prediction via Machine Learning and Algorithm Based on SSDM Big Data

9:00AM-11:00AM: Abstract Number: 1759

Rheumatoid Arthritis Affects the Ossicular Joints: A Human Otopathologic Study

9:00AM-11:00AM: Abstract Number: 1761

Rheumatoid Arthritis Inpatient Mortality: An Analysis of the National Inpatient Sample

9:00AM-11:00AM: Abstract Number: 1753

Substantial Work Limitations in Patients with Rheumatoid Arthritis Despite Optimal Treat-to-Target (T2T) Drug Therapy Intervention

9:00AM-11:00AM: Abstract Number: 1760

The Association Between the Risk of Venous Thromboembolism and Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Observational Study

9:00AM-11:00AM: Abstract Number: 1734

The Challenge of Assessing Wellbeing from the Patients` Perspective in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1754

The Point of No Return? Functional Disability in Patients with Rheumatoid Arthritis versus the General Population: Results from a Population-based Cohort Study

9:00AM-11:00AM: Abstract Number: 1744

The STAtins to Prevent Rheumatoid Arthritis (STAPRA) Trial: Clinical Results and Subsequent Qualitative Study, a Mixed Method Evaluation

9:00AM-11:00AM: Abstract Number: 1737

What Influences Fatigue Improvement in Rheumatoid Arthritis? A Prospective Cohort Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].